Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability - 2Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- 3One-third of asylum applications by Iranians approved in Germany
- 4New method spots signs of Earth's primordial life in ancient rocks
- 5Old food pyramid vs. RFK Jr.'s new food pyramid. See what's different.
- EU states agree first step for Ukraine reparations fund
- Posts falsely claim Malaysian minister to relocate public hospital for temple
- Monetary Wellness: Planning Tips for Independence from the rat race
- Vote In favor of Your Favored IT Administration
- Best Quest for new employment Site for You to Track down Amazing open doors
- Worldwide Objections Ideal For A Golf Outing
- Figure out How to Alter Your Volvo XC40 for Further developed Solace
- Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
- Remote Work Survival manual: Helping Efficiency at Home
